TIL Therapy Development Service for Bladder Cancer
The TIL (tumor-infiltrating lymphocyte) therapy is a form of cellular immunotherapy that has been utilized in the treatment of head and neck squamous cell carcinoma, melanoma, lung cancer, bladder cancer, and an expanding range of other malignancies. Alfa Cytology delivers comprehensive preclinical development services for TIL therapy specifically tailored to bladder cancer.
Introduction to TIL Therapy for Bladder Cancer
Tumor-infiltrating lymphocyte (TIL) therapy is an innovative immunotherapy for bladder cancer that leverages the body's immune cells to fight cancer. By extracting and expanding lymphocytes from the tumor, these cells are reintroduced into the patient to target and destroy cancer cells more effectively. This approach offers a promising alternative to traditional treatments, aiming to improve outcomes for patients with bladder cancer.
Fig.1. TIL therapy process. (Kazemi, M. H., et al., 2022)
Our Services
As a specialized preclinical contract research organization (CRO) exclusively focused on bladder cancer, Alfa Cytology provides a comprehensive range of services dedicated to developing TIL therapy. Our mission is to support and expedite the research and advancement of immunotherapies for bladder cancer. From initial proof of concept to preclinical trials, our services ensure an efficient, scientifically rigorous, and accurate research process. Our extensive offerings encompass but are not limited to the following.
Sample Collection and Processing
- Tumor Tissue Collection
Obtaining high-quality tumor tissue samples from animal models to ensure the integrity and quality needed for subsequent research.
- Tissue Processing
Using advanced techniques to process and pre-treat tumor tissue optimizes the extraction of highly active TIL cells, enhancing their efficacy in targeting and combating cancer cells.
TIL Cell Expansion
- Cell Isolation and Purification
Employing state-of-the-art cell separation techniques to isolate tumor-infiltrating lymphocytes from processed tumor tissue.
- In Vitro Expansion
The expansion of TIL cells is conducted under strict conditions, using optimized media and protocols to ensure both cell quantity and functional activity.
Cell Characterization
- Phenotypic Analysis
Utilizing high-precision techniques such as flow cytometry to conduct detailed phenotypic analysis of expanded TIL cells.
- Functional Assessment
Evaluating cytotoxicity and anti-tumor activity assesses TIL cells' ability to target and eradicate cancer cells, confirming their therapeutic potential.
Genetic Engineering of TILs
- Genetic Modification
Our advanced genetic engineering techniques enhance the therapeutic potential of TILs. By introducing specific genetic modifications, we can improve the efficacy and persistence of TILs in targeting bladder cancer cells.
- Enhanced Persistence and Functionality
Incorporating genes for cytokines like IL-2 or IL-15, and modifications to overcome immune checkpoint inhibitors to improve TIL proliferation, survival, and activity.
Preclinical Model Testing
- Animal Models
Testing TIL cells in bladder cancer models involves evaluating their efficacy in targeting tumors while ensuring safety and robust preclinical validation for potential therapeutic use.
- Data Analysis
Comprehensive analysis of experimental data to provide reliable support for further research and development.
Contact Us
If you are interested in gaining further insights into Alfa Cytology's TIL therapy development services or exploring potential collaborations, please do not hesitate to contact us. Our team is committed to delivering expert consultation and support, eagerly anticipating the opportunity to collaborate with you towards a brighter future.
Reference
- Kazemi, M. H., Sadri, M., and et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?. Frontiers in immunology, 2022, 13, 1018962.
For research use only. Not intended for any clinical use.
Related Services
